BNP Paribas Financial Markets
HOWL icon

BNP Paribas Financial Markets’s Werewolf Therapeutics HOWL Stock Holding History

BNP Paribas Financial Markets’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$658 Sell
790
-2
-0.3% -$1 ﹤0.01% 5515
2025
Q4 		$502 Sell
792
-1
-0.1% -$1 ﹤0.01% 5477
2025
Q3 		$1.56K Sell
793
-2,820
-78% -$3.86K ﹤0.01% 5190
2025
Q2 		$3.94K Buy
3,613
+248
+7% +$255 ﹤0.01% 4980
2025
Q1 		$3.27K Sell
3,365
-3,467
-51% -$4.54K ﹤0.01% 4921
2024
Q4 		$10.1K Buy
+6,832
New +$13.9K ﹤0.01% 4842

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets's HOWL Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Werewolf Therapeutics (HOWL) stake by 0.25% in Q1 2026, selling an estimated $1 and leaving 790 shares worth $658. The position accounts for ﹤0.01% of the portfolio, ranked #5515.

BNP Paribas Financial Markets first reported a position in HOWL in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.1K in Q4 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • BNP Paribas Financial Markets held 790 shares of Werewolf Therapeutics worth $658 as of Q1 2026.
  • BNP Paribas Financial Markets sold 2 Werewolf Therapeutics shares in Q1 2026, an estimated $1.
  • Werewolf Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5515 holding.
  • BNP Paribas Financial Markets first reported a position in Werewolf Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Werewolf Therapeutics position peaked at $10.1K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.